Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 5/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100394 | 0.90 | CDK5 (0.42) | CLK1CDK5CDK5R1IRAK4GSK3B | |
| SCHEMBL4112980 | 0.85 | DHFR (0.41) | IRAK4IRAK1 | |
| SCHEMBL4107204 | 0.85 | CLK1 (0.40) | CLK1CDK5CDK5R1IRAK4GSK3B | |
| SCHEMBL4107261 | 0.85 | CDK5 (0.40) | CLK1CDK5CDK5R1IRAK4GSK3B | |
| SCHEMBL4115467 | 0.85 | VCP (0.37) | IRAK4GSK3BIRAK1 | |
| SCHEMBL4112182 | 0.84 | ACP1 (0.45) | CLK1CDK5CDK5R1IRAK4 | |
| SCHEMBL4120199 | 0.84 | ACP1 (0.46) | CLK1CDK5CDK5R1IRAK4 | |
| SCHEMBL4107116 | 0.84 | IRAK4 (0.41) | IRAK4IRAK1 | |
| SCHEMBL4117379 | 0.83 | FGFR1 (0.49) | CLK1CDK5CDK5R1IRAK4 | |
| SCHEMBL4106463 | 0.83 | TDO2 (0.47) | CLK1CDK5CDK5R1IRAK4TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | claimed |
| US-8354407-B2 | 2-anilino-4-(heterocyclic)amino-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-2054392-A2 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA | Boehringer Ingelheim International GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2007146981-A2 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | PRKCA, PRKCG, PRKCH | CLK1 718/4885CDK5 69/4885CDK5R1 150/4885 |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | PRKCA, PRKCG, PRKCH | CLK1 718/4885CDK5 69/4885CDK5R1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.